An in vitro neurogenetics platform for precision disease modeling in the mouse science.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from science.org Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ -- Impedance-based TEER Measurement System Market Analysis by System and Consumable Products, Global Growth Oppurutunies and Revenue Forecast 2023...
Axion BioSystems Welcomes Biotech Industry Leader Julien Bradley as New CEO tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
NETRI has announced the commercial launch of its NeuroFluidics™ MEA line, developed in collaboration with Axion BioSystems and compatible with the company’s flagship Maestro MultiElectrode Array (MEA) systems. The new product line offers a range of ready-to-use compartmentalized microfluidic devices with an integrated MEA layer, providing high-throughput organs-on-chip platforms for disease research and drug discovery in neurology, dermatology, and other fields.
NETRI has announced the commercial launch of its NeuroFluidics™ MEA line, developed in collaboration with Axion BioSystems and compatible with the company’s flagship Maestro MultiElectrode Array (MEA) systems. The new product line offers a range of ready-to-use compartmentalized microfluidic devices with an integrated MEA layer, providing high-throughput organs-on-chip platforms for disease research and drug discovery in neurology, dermatology, and other fields.
Deep Learning & AI Igniting Live Cell Imaging Market Expansion the Market to Worth $3.54 Billion by 2028 – Arizton | medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.
Axion BioSystems, a leader in live-cell analysis tools, has announced the full integration of imaging innovator CytoSMART Technologies into the Axion BioSystems brand. The news, which follows the company’s 2022 acquisition of CytoSMART Technologies, reflects Axion’s expanding portfolio of live-cell analysis tools for researchers in stem cell biology, immuno-oncology, neurology, virology, toxicology, and other fields.